Skip to content
DE

BNP blood test: results, causes, and how to interpret them

Clinical review pending

BNP and NT-proBNP can signal strain on the heart. How clinical thresholds, kidney function, obesity, and medications affect interpretation, and when symptoms need urgent care.

A capped transparent sample tube contains a curled coral ribbon.

BNP is a hormone released into the blood in greater amounts when the heart is under increased strain. Testing is particularly useful when trying to establish whether heart failure is causing shortness of breath. An elevated result does not make the diagnosis on its own, however. A low result does not exclude heart disease in every situation, including in people with obesity.

In someone with acute shortness of breath, a BNP below 100 pg/mL is often used to make acute heart failure less likely. Results between 100 and 400 pg/mL are harder to interpret; above 400 pg/mL, heart failure becomes a more likely explanation. For symptoms that are not acute, the 2021 ESC guideline used a different rule-out threshold: below 35 pg/mL. These numbers address different clinical questions. They are not a general scale from “healthy” to “ill.” The 2021 ESC guideline describes their place in diagnosis; clinicians should use the diagnostic pathway applicable to the patient and current local guidance. Source

Severe or sudden shortness of breath, chest pain, fainting, or bluish lips call for urgent help. Call your local emergency number, such as 911 in the United States or 112 in the European Union, rather than waiting for a laboratory result.

What BNP is and what the test measures

BNP stands for B-type natriuretic peptide. Its older name, “brain natriuretic peptide,” explains the abbreviation, although the BNP relevant to cardiac testing comes mainly from the heart. The active hormone contains 32 amino acids. As the heart wall stretches more, or pressure or volume load increases, heart muscle cells release more natriuretic peptides.

This is initially a compensatory response: BNP helps blood vessels widen and promotes the excretion of sodium and water. In laboratory testing, its concentration provides a clue to hemodynamic stress, the pressures and flow conditions against which the heart must work. Heart failure, valve disease, high blood pressure, pulmonary embolism, and other conditions can create that stress.

BNP and NT-proBNP come from the same precursor, proBNP. NT-proBNP is an inactive fragment containing 76 amino acids. BNP has a half-life of roughly 20 minutes, compared with approximately 1–2 hours for NT-proBNP; these are estimates of how quickly concentrations decline. Their breakdown and removal differ. Neprilysin and clearance receptors help remove BNP, while kidney function is particularly important for NT-proBNP. The processes are more complicated than assigning each molecule to a single organ. The review by Daniels and Maisel explains how both markers are used for diagnosis and prognosis. Source

Because the molecules and assays differ, the same blood sample produces different numbers for BNP and NT-proBNP. There is no fixed conversion factor between them.

Decision thresholds for BNP and NT-proBNP

The table summarizes established clinical decision thresholds, including the non-acute thresholds in the 2021 ESC guideline and the age-specific acute NT-proBNP thresholds studied in ICON. “Rule out” means that heart failure becomes less likely in the appropriate clinical setting. “Higher likelihood” means that other findings must support the diagnosis. These are not ordinary reference intervals for healthy people, or a complete current referral algorithm. Newer outpatient pathways also consider age and other patient characteristics. Source

Marker Clinical setting Established decision threshold
BNP Non-acute symptoms: heart failure less likely, 2021 ESC threshold Below 35 pg/mL
BNP Acute shortness of breath: acute heart failure less likely Below 100 pg/mL
BNP Acute shortness of breath: gray zone 100–400 pg/mL
BNP Acute shortness of breath: higher likelihood of heart failure Above 400 pg/mL
NT-proBNP Non-acute symptoms: heart failure less likely, 2021 ESC threshold Below 125 pg/mL
NT-proBNP Acute shortness of breath: acute heart failure less likely Below 300 pg/mL
NT-proBNP Acute shortness of breath, age under 50: higher likelihood, ICON Above 450 pg/mL
NT-proBNP Acute shortness of breath, age 50–75: higher likelihood, ICON Above 900 pg/mL
NT-proBNP Acute shortness of breath, age over 75: higher likelihood, ICON Above 1,800 pg/mL

The age-specific NT-proBNP thresholds were studied in the ICON analysis of 1,256 patients and subsequently tested in the more recent emergency department population of ICON-RELOADED. Age, assay, and reason for testing therefore belong alongside the result. An emergency department threshold should not be transferred unchanged to the assessment of someone without symptoms. Source Source

Kidney function, body weight, heart rhythm, and medications can also affect interpretation. The number on the report is one piece of information alongside symptoms, a physical examination, an electrocardiogram, and often an ultrasound of the heart.

What can cause elevated BNP?

Causes involving the heart

Heart failure is an important cause of substantially elevated results. In heart failure with reduced ejection fraction, or HFrEF, the left ventricle pumps out a reduced proportion of the blood it contains. In heart failure with preserved ejection fraction, or HFpEF, that proportion can remain preserved even when the chamber has difficulty relaxing and filling. Both forms can raise pressure and wall stress.

BNP can exceed 400 pg/mL in HFrEF, but concentrations vary considerably; this is not a threshold that defines that form of heart failure. Levels are often more modest in HFpEF, which does not make it a harmless condition. A systematic review and meta-analysis in HFpEF examined the relationship between BNP or NT-proBNP and adverse outcomes. A Val-HeFT analysis also found prognostic information in a population with chronic heart failure. Source Source

Other possible cardiac causes include:

  • Valve disease: Aortic stenosis increases pressure load, while mitral regurgitation can cause volume overload.
  • A thickened heart muscle: Left ventricular hypertrophy may be accompanied by increased filling pressures and changes in wall stress.
  • A heart attack or another acute coronary syndrome: Reduced blood supply and regional changes in heart function can raise natriuretic peptides. A study of NT-proBNP in acute coronary syndromes examined its prognostic value. BNP does not replace an ECG or troponin testing. Source
  • Atrial fibrillation: The altered rhythm and strain on the atria can raise concentrations even without a known reduction in pumping function.

Causes beyond primary heart disease

Diseases affecting other organs can also strain the heart or change peptide concentrations. A review of BNP testing outside the emergency department discusses these situations. Source

With a pulmonary embolism, increased resistance in the lung’s blood vessels can strain the right ventricle. BNP may help assess prognosis, but it cannot independently confirm or rule out an embolism. A review of risk stratification in acute pulmonary embolism discusses this relationship. Source

Chronic kidney disease can raise NT-proBNP in particular. Reduced removal from the blood, fluid overload, and accompanying changes in the heart can all contribute. An elevated result should therefore not automatically be dismissed as “just the kidneys.”

In sepsis and severe systemic illness, inflammation, circulatory stress, and temporary changes in heart function may contribute. A study of sepsis in people without known heart failure found an association between BNP and short- and long-term mortality. That is a prognostic observation in this patient group, not evidence that sepsis and chronic heart failure are the same condition. Source

Severe anemia and hyperthyroidism can also place greater demands on the circulation and contribute to higher concentrations.

Age, sex, and medications

On average, natriuretic peptides increase with age and are often higher in women than in men. Studies of healthy adults and a community population describe these differences. They help interpret the result, but they are not reasons to ignore symptoms or an unexpected rise. Source Source

Medications can change results both by genuinely reducing strain on the heart and by affecting peptide breakdown. Sacubitril/valsartan, discussed below, is especially important.

Why BNP can be lower than expected

The effect of obesity

People with a higher BMI have lower BNP and NT-proBNP concentrations on average. This relationship has been described in a large obesity study and in two population-based studies of obesity and insulin resistance. Source Source

Possible explanations include changes in peptide production, insulin resistance, and, for BNP, increased removal through clearance receptors in fatty tissue. NT-proBNP is not broken down through that receptor in the same way, so this mechanism alone does not explain why both markers can be low.

In practice, an apparently “normal” BNP may be less reassuring in someone with obesity and characteristic symptoms. Clinical examination and, where appropriate, echocardiography remain important. The laboratory result should not be treated as an all-clear on its own.

Treatment with sacubitril/valsartan

Sacubitril/valsartan does not necessarily lower BNP. Sacubitril inhibits neprilysin, an enzyme involved in BNP breakdown. BNP may therefore rise, especially soon after treatment begins, even as the medication reduces strain on the heart. NT-proBNP is not directly broken down by neprilysin and is often easier to interpret when monitoring this situation.

PARADIGM-HF studied the combination’s clinical benefits in HFrEF. A later biomarker analysis described the different patterns of BNP and NT-proBNP during treatment. BNP does not lose all of its prognostic value. A rise needs to be considered alongside the start of treatment, symptoms, and other findings. Do not stop the medication because of a single laboratory result. Source Source

Factors that influence the result

Factor Possible effect What helps interpretation
Older age Higher concentrations on average Consider age and the relevant clinical decision thresholds.
Female sex Often higher baseline concentrations Read the result in the person’s context.
Obesity, such as a BMI above 30 Often lower concentrations Do not rely on a low result alone when symptoms are present.
Reduced kidney function Higher concentrations, particularly NT-proBNP Consider creatinine and eGFR alongside the result.
Sacubitril/valsartan BNP can rise; NT-proBNP does not share this direct breakdown effect Consider when treatment began and the pattern over time.
Atrial fibrillation Often higher concentrations Assess rhythm and structural heart findings.
Acute pulmonary embolism Possible elevation from right-heart strain Investigate the cause of shortness of breath.
Sepsis and critical illness Concentrations can rise for several reasons Assess the overall circulatory and organ findings.

A large general-population study describes NT-proBNP distributions by age and other characteristics. An analysis in HFpEF examines how kidney function and natriuretic peptides relate jointly to clinical outcomes. There is no simple correction formula that lets you subtract each influence at home. Source Source

What happens during the blood test?

Which sample is used?

BNP is usually measured in EDTA plasma. Collection often uses a K2EDTA tube with a purple label or cap, although colors vary between systems. Depending on the analyzer, NT-proBNP can be measured in serum or plasma.

A BNP of 150 pg/mL and an NT-proBNP of 150 pg/mL are clinically different findings. A direct assay comparison and the Val-HeFT comparison explain differences in measurement, concentration ranges, and prognostic information. Always check the exact test name when looking back at older results. Source Source

Do I need to fast?

Fasting is usually unnecessary for BNP or NT-proBNP alone. Other tests collected at the same time may have their own requirements. Unusually strenuous exercise just before collection may make results less comparable. In an acute situation, however, testing should not be delayed because you have eaten or have not prepared.

Timing and sample stability

BNP is more sensitive to storage and transport conditions than NT-proBNP. Processing requirements depend on the collection tube and assay; a general 2–4-hour rule is not suitable for every test. For example, Quest’s BNP instructions require separating plasma within one hour. The performing laboratory’s instructions take precedence. NT-proBNP is usually more stable, but it also has defined transport requirements. Source

In acute care, results are often available within hours. In outpatient care, timing depends on how samples reach the laboratory. Similar collection conditions are helpful for follow-up comparisons, but clinical urgency determines when a necessary test should be done.

What the gray zone means

Other findings are particularly important when a result falls between decision thresholds. BNP values of 100–400 pg/mL can occur in several conditions. REDHOT analyses of this gray zone and of clinical assessment alongside BNP illustrate why objective measurement and clinical examination need to complement each other. Source Source

Depending on the situation, the next steps may include an ECG, echocardiography, examination of the lungs, or other laboratory tests. Simply repeating BNP will not necessarily establish the cause.

Other blood tests that can help

Troponin I or T indicates injury to heart muscle cells. BNP more closely reflects strain on the heart. Both can be elevated at the same time, potentially for different reasons. An elevated troponin does not automatically mean a heart attack; the clinical findings and pattern over time must fit.

Creatinine and eGFR help assess kidney function. They are particularly important when NT-proBNP is elevated, but they do not allow an exact mathematical separation into “kidney” and “heart” components.

High-sensitivity CRP may add information about inflammation when there is a specific reason to investigate it. It is nonspecific and is not a mandatory part of every heart failure assessment. Blood lipids can contribute to long-term cardiovascular risk assessment, particularly when coronary disease is a possible cause or accompanying condition. The tests needed depend on symptoms and the findings so far.

When to take a result seriously

An isolated, mildly elevated result in a 75-year-old without symptoms means something different from the same result in a 45-year-old with sudden shortness of breath. That does not make a higher result meaningless in older age. Discuss it with your clinician and, where possible, compare it with previous measurements.

Shortness of breath, new leg swelling, a clear drop in exercise tolerance, or difficulty breathing while lying down warrant prompt medical assessment. For severe acute breathlessness, chest pain, altered consciousness, or circulatory collapse, call your local emergency number, such as 911 in the United States or 112 in the European Union. Do this whether or not a BNP result is available.

The 2021 ESC guideline and the HFA consensus on NT-proBNP algorithms connect laboratory results with further diagnostic steps, particularly echocardiography. They inform clinical decisions rather than replacing examination. The ESC published an updated heart failure guideline in 2026, and clinicians should use the currently applicable pathway. Do not adjust diuretics or other heart medications yourself on the basis of a number. Source Source Source

Frequently asked questions

What is a normal BNP result?

With acute shortness of breath, a result below 100 pg/mL often makes acute heart failure less likely. The 2021 ESC guideline used below 35 pg/mL for BNP and below 125 pg/mL for NT-proBNP in non-acute presentations. These are clinical decision aids, not universal normal values. Current outpatient pathways may also use age-specific thresholds and other patient characteristics. Source

What does a high BNP mean?

It may indicate increased pressure or volume stress on the heart. Possible causes include heart failure, valve disease, atrial fibrillation, pulmonary embolism, kidney disease, and severe systemic illness. The HFA’s practical guidance discusses these influences. The result alone does not identify the cause. Source

How do BNP and NT-proBNP differ?

BNP is the active hormone with 32 amino acids; NT-proBNP is an inactive fragment with 76. Their approximate half-lives, 20 minutes and 1–2 hours respectively, as well as their clearance pathways and assays, differ. Their patterns can diverge particularly during sacubitril/valsartan treatment, as the PARADIGM-HF biomarker analysis shows. The numbers are not interchangeable. Source

At what BNP level should I be concerned?

No single number defines an emergency. With acute shortness of breath, BNP above 400 pg/mL increases the likelihood of heart failure, as a review of acute diagnosis explains. Urgency and severity also depend on symptoms, circulation, kidney function, and other findings. Very high results need assessment; acute warning signs need immediate attention. Source

Does obesity affect the result?

Yes. BNP and NT-proBNP are often lower at a higher BMI. The obesity study and the studies of insulin resistance describe this association. A low result alone should not be treated as reassurance when characteristic symptoms are present. Source Source

What changes with kidney disease?

Reduced kidney function can raise concentrations, particularly NT-proBNP. Fluid overload and heart disease are also common in people with kidney disease. The result remains relevant and is interpreted alongside eGFR. The HFpEF kidney-function analysis examines their combined significance. Source

Do I need to fast before the test?

Usually not for BNP or NT-proBNP alone. Requirements for any other tests collected at the same time, and correct sample processing, are what matter. With acute symptoms, testing should not be postponed because you have not fasted.

Can medications lower BNP?

Effective heart failure treatment can reduce wall stress and therefore natriuretic peptides. This may occur with treatments such as ACE inhibitors, beta blockers, or mineralocorticoid receptor antagonists. Sacubitril/valsartan is a special case: BNP may rise because its breakdown is affected, while NT-proBNP behaves differently. For follow-up interpretation, it matters which medications have changed since the last measurement, as the biomarker analysis illustrates. Source

Sources